Zobrazeno 1 - 10
of 188
pro vyhledávání: '"V T DeVita"'
Publikováno v:
Oncologist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c840bff89dec390b79aaf9c2fe6ecd5
https://doi.org/10.1002/onco.13731
https://doi.org/10.1002/onco.13731
Autor:
V T DeVita, George P. Canellos
Publikováno v:
Leukemialymphoma. 57(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35e2d5481d8566ce34df95f3c0b0cb6a
https://pubmed.ncbi.nlm.nih.gov/26752549
https://pubmed.ncbi.nlm.nih.gov/26752549
Autor:
V T DeVita, George P. Canellos
The field of medical oncology has lost one of its heroes. Gianni Bonadonna died on September 6, 2015. Those of us who had the opportunity to know him and interact with him professionally remember a very intelligent, elegantly stylish, Italian gentlem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::380d116d54d4761ced3d89ea47614518
https://europepmc.org/articles/PMC4718436/
https://europepmc.org/articles/PMC4718436/
Autor:
V T DeVita
Publikováno v:
New Scientist. 228:26-27
DeVita talks about the war against cancer. The real impediment in the war is the regulatory environment and an outdated infrastructure for it, created well before people knew much about the disease. As a result, outdated beliefs persist; bureaucratic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4717d52422833199935f1afdf77cbb7c
https://doi.org/10.1016/s0262-4079(15)31556-6
https://doi.org/10.1016/s0262-4079(15)31556-6
Autor:
Robert C. Young, Dan L. Longo, Wyndham H. Wilson, V T DeVita, Robert E. Wittes, Elaine S. Jaffe, Daniel C. Ihde, A W Bastian, Susan M. Hubbard, Eli Glatstein, P L Duffey
Publikováno v:
Journal of Clinical Oncology. 15:3338-3346
PURPOSE To evaluate the efficacy and toxicity of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)/doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy plus mantle-field radiation therapy in the treatment of patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e1853f62b5811c2729aeadbdadc1bb7
https://doi.org/10.1200/jco.1997.15.11.3338
https://doi.org/10.1200/jco.1997.15.11.3338
Autor:
Robert C. Young, Susan M. Hubbard, J C Phares, V T DeVita, P L Duffey, A W Bastian, Elaine S. Jaffe, Dan L. Longo, Peter H. Wiernik
Publikováno v:
Journal of Clinical Oncology. 9:1409-1420
One hundred twenty-five assessable patients with advanced-stage Hodgkin's disease were randomized to receive mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) or MOPP alternating with lomustine (CCNU), doxorubicin, bleomycin, and stre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f65999288c344dd8680e3a0d36bcebf6
https://doi.org/10.1200/jco.1991.9.8.1409
https://doi.org/10.1200/jco.1991.9.8.1409
Publikováno v:
New England Journal of Medicine. 329:580-582
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::262fc821f5f2d52dfeb9e22300175ad6
https://doi.org/10.1056/nejm199308193290817
https://doi.org/10.1056/nejm199308193290817
Autor:
V T, DeVita, E W, Bleickardt
Publikováno v:
Cancer journal (Sudbury, Mass.). 7
Despite advances in treatment, long-term outcome of patients with diffuse large B cell lymphoma (DLBCL) is no better today than reported in 1975. A recent study applying DNA microarray technology revealed that patients whose cancer related to pattern
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::890c6305cf1c11f4284e0d52ce6ba755
https://pubmed.ncbi.nlm.nih.gov/11504281
https://pubmed.ncbi.nlm.nih.gov/11504281
Publikováno v:
Journal of Clinical Oncology. 10:1367-1369
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2d68651cb6484af366febc6364b6f31
https://doi.org/10.1200/jco.1992.10.8.1367
https://doi.org/10.1200/jco.1992.10.8.1367
Autor:
B, Burtness, M, Belker, M, Stoltz, K M, Peccerillo, L A, Lamb, S E, Chmael, A, McKeon, M B, Clark, J, Winship, J C, Marsh, G, Pizzorno, V T, DeVita
Publikováno v:
Cancer journal (Sudbury, Mass.). 6(5)
(E)-2'-fluoromethylene-2'-deoxycytidine is a novel antimetabolite. Preclinical tests have shown antiproliferative activity in various human tumor xenograft models and have also indicated that efficacy is greatest with frequent dosing schedules. We co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e9c64363efb00711cded8a9e1ba95ed7
https://pubmed.ncbi.nlm.nih.gov/11079170
https://pubmed.ncbi.nlm.nih.gov/11079170